Just a few short months ago, the Cystic Fibrosis (CF) community was making strides in their fight to have life-saving 'orphan' drugs approved in Canada.
Then COVID-19 hit, and their efforts were put aside as the government grappled with the pandemic.
Local resident, Beth Vanstone, mother of CF Warrior Madi Vanstone, spoke with BradfordToday earlier this week to discuss the challenges the CF community is now facing and the tremendous effort being made to have the government to approve orphan drugsin Canada, not only for CF patients, but for all Canadians with rare conditions and diseases.
What are orphan drugs? And why are they critical to so many Canadians?
Orphan drugs treat rare diseases. They tend to be hugelyexpensive,due to the lengthy research involved in development, and the small percentage of people needing them. There is no chance of mass-production or mass-consumption, to bring down the price.
Eighteen-year-old Madi is currently on the medication Kalydeco, another orphan drug,to treat her CF.
Madi was diagnosed with CF at nine months of age, and struggled throughout childhood with multiple hospitalizations due to her illness, often missingschool.
Six years ago, when Kalydeco was released, Madi was able to take the drug as part of a drug trial - and the Vanstones launched their battle with theOntario government, to have themedication Kalydeco covered by OHIP. Without coverage, the cost to the Vanstones - even with private insurance and a discount from the pharmaceutical company - would have come to approximately $60,000 per year.
The government did approve coverage of the medication, which she is still on today. Kalydeco has substantially improved the quality of her life.
But their fight isnt over. Madi and her mom have been working tirelessly to help other CF patients and other Canadians with rare diseases gain access to the orphan drugs they require.
There are currently three new CF modulators (drugs) from the pharmaceutical company Vertex -Orkambi, Symdeco and Trikafta -with very little access to Canadians.
Since the COVID-19 pandemic, CF Canada has reached out to the government and Vertex Pharmaceuticals to allow CF patients access to all current and future CF modulators.
In a letter to the federal government,CEO of CF Canada Kelly Glover noted that the pharmaceutical company Vertex had recently made an offer to the pan-Canadian Pharmaceutical Alliance (pCPA), and urged the government to negotiate on the offer right away.
Cystic fibrosis is a fatal disease," Glover wrote. "Similar to COVID-19 it affects primarily the respiratory system. Similar to COVID-19, it kills people. Unlike COVID-19 its much more efficient, just slower. Eighty five percent of people with CF will die from respiratory failure, but CF will ultimately kill them all, as compared to only about 1-2% for COVID. But instead of dying in weeks, CF slowly deprives everyone with CF of quality of life. Our 4,300 patients spent a total 26,500 days in hospital in 2018. Thats 72 years! Seventy-two years worth of hospital resources that could be better spent taking care of people with COVID-19.
But the pCPA has indicated that it is not negotiating a deal for two of the three CF modulators, Orkambi and Symdeco, but isonly considering negotiating for Trikafta, once it is approved by Health Canada. Currently Trikafta can only be made available in compassionate cases if the patient meets specific criteria.
Our community is so vulnerable, having underlying respiratory issues already, said Beth, worried about the additional impact of COVID-19.
Everyday our people have to be six feet a part, everyday if theres somebody sick we cant go to them. Our kids cant touch things because they can get sick and end up in the hospital, she said.This is our life. Everyones getting a little test of what its like to have CF.
A response from the pCPA Governing Council stated, The pan-Canadian Pharmaceutical Alliance (pCPA) recognizes that this is a challenging time, especially for cystic fibrosis patients during the COVID-19 pandemic.
The Council noted that they have held numerous meetings with Vertex, hoping to reach an agreement to improve access to drug treatments for cystic fibrosis patients. The alliance continues to encourage Vertex to submit Trikafta to Health Canada and if approved, to then submit it to Canadian Agency for Drugs and Technology in Health (CADTH) or lInstitut national dexcellence en sant et en services sociaux (INESSS) for a Health Technology Assessment (HTA) review, the response stated.
The cPCA declined to providedetails of the discussionswith Vertex due to confidentiality reasons, but noted, the pCPA continues to engage with Vertex with the goal of bringing new cystic fibrosis medications to the Canadian market."
Beth and the rest of the CF community point to a disparity: governments are providing unlimited funding forCOVID-19 patient care, but there is alack of funding of treatment for CF patients who suffer breathing issues everyday.
We will spend whatever, and shut down our country, to save people from COVID, said Beth, yet it's too expensive to pay for the medications for CF patientsthat could ease the suffering, and reduce hospitalizations.
You cant help but take it a little personal, she said. Its really frustrating that the government doesnt seem to care.
She also worries that,with the new rules for the Patented Medicine Prices Review Board (PMPRB) set to come into effect this July, it will be even more difficult for companies like Vertex to market in Canada, due to the high price of orphan drugs.
The new rules and regulations for lowering the cost of medications for patients across Canada are supposed to take effect in July 2020. The PMPRB has said itwill be publishing an updated version of its draft pricing Guidelines for public consultation in the coming weeks.
This document is responsive to stakeholder feedback, including concerns from patient advocacy groups about the impact of the pending changes on access to promising new drug therapies, said Communications Advisor for the PMPRB, Jeff Wright.
Beth Vanstone is currently working with the group CF Get Loud, which has joined forces with CORD (Canadian Organization for Rare Disease) to oppose the PMPRB changes.
They (CORD) represent the rare disease community, and of course innovative therapies are so expensive for them as well, so they are going to be cut off from medications as well, she explained.
Simcoe-Grey MP Terry Dowdall has been working with the Vanstones and the CF community, to gettheir voices heard. He recently raised his concerns in the House of Commons, in an effort to have Patty Hajdu rescind the changes to the PMPRB.
"You are seeing how money can become available for certain issues," he explained, referring to the government spending on COVID-19, "Health is number one, we really need to take care of Canadians here in our homeland."
He belives the longterm costs of keeping CF patients in hospitals and on disability, far outweigh the costs of their needed medications.
"We're going to keep pushing it and Ihope one day its not an issue," he said. "I'm hoping the government does the right thing."
We are pushing that the changes be rescinded or an implementation date be changed to 2022 where they are apparently coming up with a rare disease strategy, Beth said.When they have a path set up for rare diseases in 2022, implement the changes at that time so orphan drugs can stream off on their own.
She is hoping that way, future drugs for rare diseases will not have to go through the same restrictive criteria.
What the PMPRB is doing right now is deciding for all Canadians what medications they will have access to, and its a very small percentage of whats available to everyone else in the world, Vanstone said. And instead of improving negotiations with pharmaceutical companies,theyre taking that opportunity right out, she said.
Wright, responding for PMPRB, stated thatIf any business decisions affecting Canada are being contemplated by pharmaceutical companies as a result of the draft Guidelines, it would be premature to take them until such time as the document is finalized.
He added that manufacturers don't need the PMPRBs prior approval of their price in order to launch drugs in Canada.
Beth is worried that, with all the emphasis on cost-savings,Canadians are not seeing the 'bigger picture' andthe implications of the PMPRB, especially for orphan drugs.
These drugs are available everywhere else. Noother country is doing something like this, she fumed. Its a war against big pharma, and patients are the casualties. Its heartbreaking."
The Vanstones and the rest of the CF community feel like they are on the wrong side in a losing battle.
I really have always thought people came first in Canada, until getting involved in this kind of scene and seeing that its not really true, Beth said.
As for the PMPRB, I think it was a really poorly thought-out plan, and now theyve dug their heels in, she said, noting that the plan may be a good idea for general medications for things like a cold, but not for those whoneed innovative life-saving medicines for rare diseases.
On June 3, the CF Get Loud community will be hosting a virtual Town Hall for patient advocacy, calling on Federal Health Minister of Canada Patty Hajdu and other MPs to rescind the changes in the PMPRB, so that the drugs can be submitted to help save patients lives.
Bethencourages anyoneinterested in learning more about the future of Canadas health care system in relation to new and innovative medications, to tune in.
Its not just going to be about CF," she said. "Its about our (health care) system and whats happening.
Link:
Local mother, daughter 'getting loud' for CF and the need for lifesaving medication - BradfordToday
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Soccer ... - Lowes Corporate - April 20th, 2024 [April 20th, 2024]
- Canyon Endurace CF SLX 8 AXS Aero All in the name of speed and distance? - GRAN FONDO Cycling Magazine - April 20th, 2024 [April 20th, 2024]
- Porosome treatment targeting CFTR shows promise in CF models - Cystic Fibrosis News Today - April 20th, 2024 [April 20th, 2024]
- The Reign of Girls Generation's YoonA in Endorsements: The CF Queen - allkpop - April 20th, 2024 [April 20th, 2024]
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Ftbol ... - Inter Miami CF - April 20th, 2024 [April 20th, 2024]
- The changing epidemiology of pulmonary infection in children and adolescents with cystic fibrosis: an 18-year ... - Nature.com - April 20th, 2024 [April 20th, 2024]
- Controlling anxiety is a key part of managing my health with CF - Cystic Fibrosis News Today - April 20th, 2024 [April 20th, 2024]
- Orlando City at CF Montreal: Three Keys to Victory - The Mane Land - April 20th, 2024 [April 20th, 2024]
- Learn to Evaluate (CF) using the Charts - Stock Traders Daily - April 20th, 2024 [April 20th, 2024]
- CF Industries and JERA Announce Joint Development Agreement to Develop Greenfield Low-Carbon Ammonia ... - Business Wire - April 20th, 2024 [April 20th, 2024]
- CF Montreal plays Orlando City in conference action - FOX Sports - April 20th, 2024 [April 20th, 2024]
- CF Montral: What is the ceiling for Josef Martnez's new team? | MLSSoccer.com - MLSsoccer.com - April 20th, 2024 [April 20th, 2024]
- Spotlight on CF Industries Holdings: Analyzing the Surge in Options Activity - CF Industries Holdings (NY - Benzinga - April 20th, 2024 [April 20th, 2024]
- Mamardashvili boast the highest spot-kick saves this season - Valencia CF - April 20th, 2024 [April 20th, 2024]
- Jaume Domnech: "I have the VCF DNA inside me" - Valencia CF - April 20th, 2024 [April 20th, 2024]
- MATCH RECAP: Inter Miami CF Earns 2-3 Win on the Road Over Sporting Kansas City at a Packed Arrowhead Stadium - Inter Miami CF - April 20th, 2024 [April 20th, 2024]
- Pavel "The Experiment" Dailidko: Undefeated in 2023 and Charging into BRAVE CF 81 this Saturday, April 20 - Black Belt Magazine - April 20th, 2024 [April 20th, 2024]
- JERA and CF Industries Holdings sing ammonia production deal - SAFETY4SEA - April 20th, 2024 [April 20th, 2024]
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Soccer ... - PR Newswire - April 20th, 2024 [April 20th, 2024]
- CF Industries Holdings, Inc. (NYSE:CF) Shares Purchased by Mirae Asset Global Investments Co. Ltd. - Defense World - April 20th, 2024 [April 20th, 2024]
- CF: Milan to jump above Juventus in UEFA ranking for first time in 10 years - Sempre Milan - April 20th, 2024 [April 20th, 2024]
- Color Star's Partner Team Villarreal CF Bests Real Madrid CF Once Again As The Yellow Submarine Maintains Its Impressive Win Record -... - April 19th, 2023 [April 19th, 2023]
- Brave CF 70 Slovenia: Joilton Lutterbach vs. Andreas Gustafsson; Date, fight times, how to watch on DAZN - dazn.com - April 19th, 2023 [April 19th, 2023]
- Malaga CF owner Sheikh Al-Thani vows never to put the club he has run into the ground up for sale - The Olive Press - April 19th, 2023 [April 19th, 2023]
- CF Industries partnering with South Korea firm on $2 billion blue ammonia project in Ascension - The Advocate - March 4th, 2023 [March 4th, 2023]
- Cystic Fibrosis (CF): Causes, Symptoms, Diagnosis & Treatment - February 7th, 2023 [February 7th, 2023]
- Reg CF: 2022 Delivered A Decline For Investment Crowdfunding As Economy Slowed, But Expectations Going - Crowdfund Insider - February 7th, 2023 [February 7th, 2023]
- Cystic fibrosis life expectancy: Averages by stage and age - February 2nd, 2023 [February 2nd, 2023]
- Cystic Fibrosis Carrier: What You Should Know - Healthline - February 2nd, 2023 [February 2nd, 2023]
- Cystic Fibrosis: Prenatal Screening and Diagnosis | ACOG - February 2nd, 2023 [February 2nd, 2023]
- CF Moto to launch a retro mini bike, will compete with Honda Grom in the international markets, all we know so far - DNP INDIA - February 2nd, 2023 [February 2nd, 2023]
- CF Industries Holdings, Inc. (NYSE:CF) Short Interest Down 10.3% in October - MarketBeat - November 16th, 2022 [November 16th, 2022]
- Will CF Industries Holdings, Inc. (CF) Stay at the Top of the Basic Materials Sector? - InvestorsObserver - October 25th, 2022 [October 25th, 2022]
- Wanyama on Sunday played his last match for CF Montreal- Here are potential destinations - The Standard - October 25th, 2022 [October 25th, 2022]
- Scouting Report: 5 things you should know about CF Montral when they play NYCFC in the MLS Cup Playoffs - Hudson River Blue - October 21st, 2022 [October 21st, 2022]
- 2-year-old living with cystic fibrosis helped by new treatments - 11Alive.com WXIA - October 13th, 2022 [October 13th, 2022]
- Phage Trial to Treat CF Patients with Multi-Drug Resistant Bacterial Infections - UC San Diego Health - October 13th, 2022 [October 13th, 2022]
- High Blood-sugar Levels at Night Affect Lung Function in CF Adults... - Cystic Fibrosis News Today - October 13th, 2022 [October 13th, 2022]
- This 7-year-old is finally on a 'life-changing' cystic fibrosis drug. For others in Ontario, access is tricky - CBC.ca - October 13th, 2022 [October 13th, 2022]
- CF's Thomas and Easttam dodge Panthers' high-powered defense, tackle running offense head-on - Camden News - October 13th, 2022 [October 13th, 2022]
- The Difficulties of Diving Back In After Taking a Hiatus | Cystic... - Cystic Fibrosis News Today - October 13th, 2022 [October 13th, 2022]
- Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswire - October 13th, 2022 [October 13th, 2022]
- Massive Predictions: Columbus Crew at CF Montral - Massive Report - September 9th, 2022 [September 9th, 2022]
- Why CF Acquisition Corp. VI Blasted 14% Higher Today - The Motley Fool - September 9th, 2022 [September 9th, 2022]
- Watch Real Betis vs. Villarreal CF Online: Live Stream, Start Time - For The Win - September 9th, 2022 [September 9th, 2022]
- Watch Getafe CF vs. Real Sociedad Online: Live Stream, Start Time - For The Win - September 9th, 2022 [September 9th, 2022]
- Mauro Icardi linked with move to Inter Miami CF - AS USA - September 9th, 2022 [September 9th, 2022]
- CF Acquisition (NASDAQ:CFVI) Rumble Takes On Traditional Media Outlets With New 'Rumble Exclusives' Liv - Benzinga - September 9th, 2022 [September 9th, 2022]
- SF Giants CF struggles on triple by Klay's brother - SFGATE - July 25th, 2022 [July 25th, 2022]
- CF Industries Holdings, Inc. Statement Regarding ITC Injury Determination Concerning Imports of UAN from Russia and Trinidad and Tobago - Business... - July 25th, 2022 [July 25th, 2022]
- CF man jailed in hit-and-run case - Leader-Telegram - July 25th, 2022 [July 25th, 2022]
- AEG and Socios.com Launch Partnership for the Inaugural Soccer Champions Tour Featuring Real Madrid CF, FC Barcelona, Juventus, Club America and Club... - July 25th, 2022 [July 25th, 2022]
- Taty Castellanos plays his final game for NYCFC in 2-0 home win - Hudson River Blue - July 25th, 2022 [July 25th, 2022]
- Padres' Fernando Tatis Jr.: Position Change to CF from SS 'Not out of the Question' - Bleacher Report - July 25th, 2022 [July 25th, 2022]
- CF Industries Stock: From Boom To Bust - Sell Into The Rallies (NYSE:CF) - Seeking Alpha - June 20th, 2022 [June 20th, 2022]
- CF graduates to chart their own paths to success - Valley Breeze - June 20th, 2022 [June 20th, 2022]
- Poirier: We need the strength of the fans" - Real Madrid CF - June 20th, 2022 [June 20th, 2022]
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis... - June 11th, 2022 [June 11th, 2022]
- Jayda Coleman, Oklahoma CF, robs Texas of a home run at the wall - Saturday Down South - June 11th, 2022 [June 11th, 2022]
- Gennaro Gattuso brings tenacity and technique to the Valencia CF dugout - Yardbarker - June 11th, 2022 [June 11th, 2022]
- 77-85: On to the league final - Real Madrid CF - June 11th, 2022 [June 11th, 2022]
- Gator Greats On CF Hall of Fame Ballot - ESPN 98.1 FM - 850 AM WRUF - WRUF - June 11th, 2022 [June 11th, 2022]
- Mariners CF Julio Rodrguez named AL Rookie of the Month for May - Seattle Sports - June 5th, 2022 [June 5th, 2022]
- CF woman charged with theft of trade secrets from former employer - Leader-Telegram - June 5th, 2022 [June 5th, 2022]
- Laso: The team were magnificent in defense" - Real Madrid CF - June 5th, 2022 [June 5th, 2022]
- The Austrian Wonderboy Returns To Action At BRAVE CF 59 in Uzbekistan - FightBook MMA - June 5th, 2022 [June 5th, 2022]
- Son Ye Jin Teases Fans With First CF Since Wedding to Hyun Bin - Kdramastars - June 5th, 2022 [June 5th, 2022]
- Fourth anniversary of the Duodcima - Real Madrid CF - June 5th, 2022 [June 5th, 2022]
- Meet the Avro CF-105 Arrow: The Long-Ranger Fighter Designed to Battle Russia - 19FortyFive - June 5th, 2022 [June 5th, 2022]
- Charlottetown to host professional soccer match between Sunderland AFC, CF Montral U23 teams - Saltwire - June 5th, 2022 [June 5th, 2022]
- Neutrophil Dysfunction in the Pathogenesis of Cystic Fibrosis (CF) - Physician's Weekly - May 21st, 2022 [May 21st, 2022]
- CF Industries Holdings, Inc. (NYSE:CF) Expected to Announce Earnings of $6.16 Per Share - Defense World - May 21st, 2022 [May 21st, 2022]
- Living with Cystic Fibrosis: A CF patient experience story | LHSC - London Health Sciences Centre - May 21st, 2022 [May 21st, 2022]
- CF Montreals Ismal Kon is showing impressive promise early this MLS season - The Athletic - May 21st, 2022 [May 21st, 2022]
- Film produced by CF native to be shown at Micon Cinemas - Leader-Telegram - May 21st, 2022 [May 21st, 2022]
- CF & CFRP Market Research Report by Carbon Fiber Materials, Resin Type, Manufacturing Process, End-use Industry, Region - Global Forecast to 2027... - May 21st, 2022 [May 21st, 2022]
- Experienced defensive backs for CF thriving this off-season - Camden News - May 21st, 2022 [May 21st, 2022]
- The 37th anniversary of Real Madrid's first UEFA Cup - Real Madrid CF - May 21st, 2022 [May 21st, 2022]
- Q&A: How a Cystic fibrosis diagnosis has changed in recent years - WRAL News - May 6th, 2022 [May 6th, 2022]
- Kinnear: Hope, Turning CF Into 'Cure Found' and Betting on the Long Shot - insidelacrosse.com - May 6th, 2022 [May 6th, 2022]